ArticleNeuroImage. Clinical2021
FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD.
Article in NeuroImage. Clinical, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Neuroanatomical and clinical correlates of prodromal dementia with Lewy bodies: a systematic literature review of neuroimaging findings.Journal of neurology · 2024Pooled it
- Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Pooled it
- Dorsal and ventral stream visuoperceptual processing deficits in Lewy body disease.Journal of neurology · 2026Article
- A false discovery rate control method using a fully connected hidden Markov random field for neuroimaging data.Medical image analysis · 2026Article
- Effect of genetic factors on [European journal of nuclear medicine and molecular imaging · 2026Article
- Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.Journal of biomedical science · 2026Article
- Skin Biopsy for Phosphorylated α-Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stages.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape.Journal of nuclear medicine technology · 2026Review
- The role of brain MR and FDG-PET in the diagnosis of neurodegenerative disease.European radiology · 2026Review
- Normal cerebral oxygen consumption and lactate levels in patients with Alzheimer's disease and Lewy body dementia.GeroScience · 2026Article
- Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein.Molecular neurodegeneration · 2025Review
- The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients.Brain : a journal of neurology · 2025Article
- Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?Nature reviews. Neurology · 2025Review
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer's disease copathologies.NPJ Parkinson's disease · 2025Article
- Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum.JAMA neurology · 2025Article
- Clinical validity and reproducibility of a visual rating scale for cingulate island sign in a real-world memory clinic: An FDG-PET/MRI study.European journal of neurology · 2025Article
- Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease.Nature communications · 2024Observational
- Potential dopaminergic deficit in patients with geriatric psychiatric disorders as revealed by DAT-SPECT: a cross-sectional study.BMJ mental health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 1 country.
Funding
Abstract
background and purposePatients with dementia with Lewy bodies (DLB) are characterized by hypometabolism in the parieto-occipital cortex and the cingulate island sign (CIS) on
methodsPatients with MCI from the Mayo Clinic Alzheimer's Disease Research Center who underwent FDG PET at baseline and progressed to either probable DLB (MCI-DLB; n = 17) or AD dementia (MCI-AD; n = 41) during follow-up, and a comparison cohort of CU controls (n = 100) were included.
resultsPatients with MCI-DLB had hypometabolism in the parieto-occipital cortex extending into temporal lobes, substantia nigra and thalamus. When compared to MCI-AD, medial temporal and posterior cingulate metabolism were preserved in patients with MCI-DLB, accompanied by greater hypometabolism in the substantia nigra in MCI-DLB compared to MCI-AD. In distinguishing MCI-DLB from MCI-AD at the maximum value of Youden's index, CIS ratio was highly specific (90%) but not sensitive (59%), but a higher medial temporal to substantia nigra ratio was both sensitive (94%) and specific (83%).
conclusionFDG PET is a potential biomarker for the prodromal stage of DLB. A higher medial temporal metabolism and CIS ratio, and lower substantia nigra metabolism have additive value in distinguishing prodromal DLB and AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.